BIONICS 38 mm Trial EluNIR Ridaforolimus Eluting Coronary Stent System (EluNIR) In Coronary Stenosis Trial

Summary

This is a prospective, multi-center, single-arm, open-label clinical trial. Clinical follow-up will be performed at 30 days. Follow-up by phone will be performed at 6 months, and 1 year after the procedure. Study Objective is to further assess the safety and efficacy of long (38 mm) Ridaforolimus Eluting Stent - EluNIR.

Timeline

Start

2018-11-14

Primary completion

2019-03-01

Completion

2020-04-30

Publications

• Jonas M, Ben-Yehuda O, Banai S, Segev A, Danenberg H, Assali A, Tuvali O, Haberman D, Chernin G. Percutaneous coronary intervention with ridaforolimus-eluting stents in long lesions: the BIONICS 38 mm prospective trial. Coron Artery Dis. 2023 Sep 1;34(6):410-414. doi: 10.1097/MCA.0000000000001264. Epub 2023 Jul 4.

Drugs

Indications